Management of Individuals Requiring Antiretroviral Therapy and TB Treatment

Overview

Journal Curr Opin HIV AIDS

Specialty Infectious Diseases

Date 2010 Jan 5

PMID 20046149

Citations 35

Authors

Karen Cohen

Graeme Meintjes

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Globally, tuberculosis (TB) is the commonest opportunistic infection in people living with HIV. Many co-infected patients first present with advanced immunosuppression and require antiretroviral therapy (ART) initiation during TB treatment. The incidence of TB in patients established on ART remains high. Co-treatment presents several management challenges. Recent data on these management issues are reviewed.

Recent Findings: Efavirenz concentrations at standard doses are similar with and without concomitant rifampicin-based TB treatment. Nevirapine concentrations are frequently subtherapeutic during lead-in dosing at 200 mg daily in patients on rifampicin-based TB treatment, which may result in inferior virological outcomes. Hepatotoxicity occurred in three pharmacokinetic studies (conducted in healthy volunteers) of boosted protease inhibitors initiated in participants on rifampicin. Results of a clinical trial comparing efavirenz-based and nevirapine-based ART in patients on TB treatment, with no lead-in dosing of nevirapine, are awaited. Concurrent TB treatment increases the need for stavudine substitutions, mainly related to neuropathy. Consensus case definitions for TB immune reconstitution inflammatory syndrome (TB-IRIS) have been published. It is important to exclude TB drug resistance in patients with suspected TB-IRIS. A clinical trial demonstrated benefit of prednisone for treating TB-IRIS, reducing a combined endpoint of days of hospitalization and outpatient therapeutic procedures. Starting ART during TB treatment improved survival in patients with CD4 cell count less than 500 cells/mul, but the optimal interval between starting TB treatment and starting ART remains to be determined in several ongoing trials.

Summary: ART improves survival in co-infected TB patients, but is complicated by several management challenges that compromise programmatic implementation in resource-limited settings. Recent findings and the findings of ongoing studies will assist clinicians in dealing with these challenges.

Citing Articles

Active tuberculosis disease among people living with HIV on ART who completed tuberculosis preventive therapy at three public hospitals in Uganda.

Turinawe G, Asaasira D, Kajumba M, Mugumya I, Walusimbi D, Tebagalika F PLoS One. 2024; 19(11):e0313284.

PMID: 39527556 PMC: 11554154. DOI: 10.1371/journal.pone.0313284.

A Comprehensive Review of HIV-Associated Tuberculosis: Clinical Challenges and Advances in Management.

Patel A, Pundkar A, Agarwal A, Gadkari C, Nagpal A, Kuttan N Cureus. 2024; 16(9):e68784.

PMID: 39371702 PMC: 11456262. DOI: 10.7759/cureus.68784.

Effect of tuberculosis-HIV co-treatment on clinical and growth outcomes among hospitalized children newly initiating antiretroviral therapy.

Cherkos A, Cranmer L, Njuguna I, LaCourse S, Mugo C, Moraa H AIDS. 2023; 38(4):579-588.

PMID: 38016160 PMC: 10922257. DOI: 10.1097/QAD.0000000000003797.

Understanding the Decline of Incident, Active Tuberculosis in People With Human Immunodeficiency Virus in Switzerland.

Zeeb M, Tepekule B, Kusejko K, Reiber C, Kalin M, Bartl L Clin Infect Dis. 2023; 77(9):1303-1311.

PMID: 37257071 PMC: 10640694. DOI: 10.1093/cid/ciad330.

Prednisone for the prevention of tuberculosis-associated IRIS (randomized controlled trial): Impact on the health-related quality of life.

Wouters E, Stek C, Swartz A, Buyze J, Schutz C, Thienemann F Front Psychol. 2022; 13:983028.

PMID: 36275235 PMC: 9581134. DOI: 10.3389/fpsyg.2022.983028.

References

Baalwa J, Mayanja-Kizza H, Kamya M, John L, Kambugu A, Colebunders R . Worsening and unmasking of tuberculosis in HIV-1 infected patients after initiating highly active anti-retroviral therapy in Uganda. Afr Health Sci. 2009; 8(3):190-5. PMC: 2583270. View

Boulle A, Van Cutsem G, Cohen K, Hilderbrand K, Mathee S, Abrahams M . Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA. 2008; 300(5):530-9. DOI: 10.1001/jama.300.5.530. View

Lawn S, Wainwright H, Orrell C . Fatal unmasking tuberculosis immune reconstitution disease with bronchiolitis obliterans organizing pneumonia: the role of macrophages. AIDS. 2008; 23(1):143-5. DOI: 10.1097/QAD.0b013e32831d2a98. View

Harries A, Zachariah R, Lawn S . Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa. Int J Tuberc Lung Dis. 2008; 13(1):6-16. View

la Porte C, Colbers E, Bertz R, Voncken D, Wikstrom K, Boeree M . Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother. 2004; 48(5):1553-60. PMC: 400571. DOI: 10.1128/AAC.48.5.1553-1560.2004. View

Westreich D, MacPhail P, Van Rie A, Malope-Kgokong B, Ive P, Rubel D . Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS. 2009; 23(6):707-15. PMC: 2848384. DOI: 10.1097/QAD.0b013e328325d115. View

Haas D, Koletar S, Laughlin L, Kendall M, Suckow C, Gerber J . Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr. 2009; 50(3):290-3. PMC: 2653210. DOI: 10.1097/QAI.0b013e318189a7df. View

Avihingsanon A, Manosuthi W, Kantipong P, Chuchotaworn C, Moolphate S, Sakornjun W . Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin. Antivir Ther. 2008; 13(4):529-36. View

Pollard R, Robinson P, Dransfield K . Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther. 1999; 20(6):1071-92. DOI: 10.1016/s0149-2918(98)80105-7. View

10.

Pepper D, Marais S, Maartens G, Rebe K, Morroni C, Rangaka M . Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin Infect Dis. 2009; 48(11):e96-107. DOI: 10.1086/598988. View

11.

Akksilp S, Karnkawinpong O, Wattanaamornkiat W, Viriyakitja D, Monkongdee P, Sitti W . Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand. Emerg Infect Dis. 2008; 13(7):1001-7. PMC: 2878231. DOI: 10.3201/eid1307.061506. View

12.

Pepper D, Rebe K, Morroni C, Wilkinson R, Meintjes G . Clinical deterioration during antitubercular treatment at a district hospital in South Africa: the importance of drug resistance and AIDS defining illnesses. PLoS One. 2009; 4(2):e4520. PMC: 2642598. DOI: 10.1371/journal.pone.0004520. View

13.

Niemi M, Backman J, Fromm M, Neuvonen P, Kivisto K . Pharmacokinetic interactions with rifampicin : clinical relevance. Clin Pharmacokinet. 2003; 42(9):819-50. DOI: 10.2165/00003088-200342090-00003. View

14.

Friedland G . Tuberculosis immune reconstitution inflammatory syndrome: drug resistance and the critical need for better diagnostics. Clin Infect Dis. 2009; 48(5):677-9. DOI: 10.1086/596765. View

15.

Meintjes G, Rangaka M, Maartens G, Rebe K, Morroni C, Pepper D . Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis. 2009; 48(5):667-76. PMC: 2737129. DOI: 10.1086/596764. View

16.

Nijland H, Lhomme R, Rongen G, van Uden P, van Crevel R, Boeree M . High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS. 2008; 22(8):931-5. DOI: 10.1097/QAD.0b013e3282faa71e. View

17.

Lawn S, Churchyard G . Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS. 2009; 4(4):325-33. PMC: 4233405. DOI: 10.1097/COH.0b013e32832c7d61. View

18.

Breen R, Smith C, Bettinson H, Dart S, Bannister B, Johnson M . Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax. 2004; 59(8):704-7. PMC: 1747098. DOI: 10.1136/thx.2003.019224. View

19.

Manabe Y, Breen R, Perti T, Girardi E, Sterling T . Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. J Infect Dis. 2008; 199(3):437-44. DOI: 10.1086/595985. View

20.

Tahir M, Sinha S, Sharma S, Mitsuyasu R . Immune reconstitution inflammatory syndrome manifesting as disseminated tuberculosis, deep venous thrombosis, encephalopathy and myelopathy. Indian J Chest Dis Allied Sci. 2008; 50(4):363-4. View